Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 16/20 | 0.43 |
| ▸ | PRKCA | P17252 | 7/20 | 0.43 |
| ▸ | PRKCD | Q05655 | 6/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.38 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8965391 | 0.81 | PRKCQ (0.50) | PRKCQPRKCAPRKCDMAP4K3 | |
| SCHEMBL8965580 | 0.78 | PRKCQ (0.48) | PRKCQPRKCAPRKCD | |
| SCHEMBL8965220 | 0.76 | PRKCQ (0.52) | PRKCQPRKCAPRKCDMAP4K3 | |
| SCHEMBL8965474 | 0.69 | PRKCQ (0.70) | PRKCQPRKCAPRKCD | |
| SCHEMBL8965771 | 0.68 | PRKCQ (0.67) | PRKCQPRKCAPRKCD | |
| SCHEMBL12400006 | 0.67 | PRKCQ (0.39) | PRKCQPRKCAPRKCDPAK1 | |
| SCHEMBL8964393 | 0.66 | PRKCQ (0.60) | PRKCQPRKCAPRKCD | |
| SCHEMBL8965670 | 0.65 | PRKCQ (0.70) | PRKCQPRKCAPRKCD | |
| SCHEMBL8965889 | 0.65 | PRKCQ (0.57) | PRKCQPRKCAPRKCD | |
| SCHEMBL31226866 | 0.64 | IRAK4 (0.49) | IRAK4JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221334-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221334-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | US | disclosed |
| US-8741931-B2 | Kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2014-06-03 | — | — | US | disclosed |
| US-8741931-B2 | Kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2014-06-03 | — | — | US | disclosed |
| US-20120214799-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120214799-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-23 | — | — | US | disclosed |
| US-8188071-B2 | Amino substituted pyridines as potent kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188071-B2 | Amino substituted pyridines as potent kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090124602-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-14 | — | — | US | disclosed |
| US-20090124602-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221334-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | PRKCQ 38/4885PRKCA 25/4885PRKCD 120/4885 |
| US-20120214799-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | PRKCQ 38/4885PRKCA 25/4885PRKCD 120/4885 |
| US-20090124602-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | PRKCQ 38/4885PRKCA 25/4885PRKCD 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.